Special Issue "Cytokine Growth Factor Antibodies in Immunotherapy"
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (30 April 2013)
Dr. Cecile King
Immunology Program, The Garvan Institute of Medical Research, 384 Victoria Street Darlinghurst, NSW, 2010, Australia
Phone: +61 2 92958370
Fax: +61 2 92958404
Interests: ADCC; neutralizing antibodies; cytokines; IL-21; IL-22; T cells, B cells; autoimmune disease; mucosal autoimmunity
In this issue, we aim to draw together some of the latest research on antibodies directed against cytokines used in both research and clinical settings. Cytokines are small cell-signaling protein molecules secreted by cells of the immune system that regulate host responses to infection, inflammation, and trauma. Cytokines deliver signals between cells, and often across short distances during cell-to-cell interactions, which influence cellular growth and differentiation.
Antibodies directed against cytokines have had an enormous impact on biomedical research. Research Laboratories, pharmaceutical and biotechnology industries continue to focus on the development of antibodies directed against cytokines for the treatment of cancer, chronic inflammation and autoimmune diseases. Attention has focused on blocking cytokines, which are harmful to the host and using antibodies bound to cytokines to expand subsets of T cells that can regulate immune responses. Strategies include neutralizing antibodies, cytokine-cytokine antibody complexes, soluble receptors, receptor antagonist and targeting molecules that are important for the processing of cytokines.
Dr. Cecile King
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- growth factors
- anti-cytokine antibodies
- immune complexes
- cytokine receptor trap
- potentiating antibodies
- neutralizing antibodies
Article: Characterization of a Phospho-Specific Antibody to the Fcε Receptor γ Chain, Reveals Differences in the Regulation of Syk and Akt Phosphorylation
Antibodies 2013, 2(2), 321-337; doi:10.3390/antib2020321
Received: 10 April 2013; in revised form: 20 April 2013 / Accepted: 3 May 2013 / Published: 13 May 2013| Download PDF Full-text (962 KB) | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Molecular Engineering of Cytokine Therapeutics
Authors: Rodrigo Vazquez-Lombardi and Daniel Christ
Affiliations: Garvan Institute of Medical Research, 384 Victoria Rd, Darlinghurst NSW 2010 Sydney, Australia
Abstract: Over the past three decades a large body of work has been directed at the development of therapeutic cytokines. Despite their central role in immune modulation, only a handful of cytokine therapeutics has achieved regulatory approval. One of the major challenges associated with the therapeutic use of cytokines relates to their short serum half-life and low bioavailability. High doses are required to overcome these problems, which often result in dose-limiting toxicities. Consequently, most cytokines require protein engineering approaches to reduce toxicity and increase half-life. For this purpose, PEGylation, fusion proteins, antibody complexes and mutagenesis have been utilized. Here we summarise recent advances and emerging strategies in this area.
Last update: 20 February 2013